Mirae Asset Global Etfs Holdings Ltd. Coherus Bio Sciences, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 53,691 shares of CHRS stock, worth $41,878. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,691Holding current value
$41,878% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
140Shares Held
76.7MCall Options Held
79.1KPut Options Held
100K-
Black Rock Inc. New York, NY11.8MShares$9.17 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$8.27 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$8.11 Million0.53% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$2.37 Million0.3% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.84MShares$2.22 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $60.6M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...